Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 473-479

  Schneider, P M ^a   Praeuer, H W ^b   Stoeltzing, O ^a   Boehm, J ^b   Manning, J ^c   Metzger, R ^a   Fink, U ^b   Wegerer, S ^b   Hoelscher, A H ^a   Roth, J A ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

c erbB 2; Ki ras; Lung cancer; p53; Prognosis; Tumour suppressor gene

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; TISSUE SECTION;

EID: 0033931517     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1287     Document Type: Article

References (47)

1. Altman DG, Lausen B, Sauerbrci W and Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
2. Boenisch T (1989) Staining methods, controls, background. In: Handbook Immunochemical Staining Methods. Dako Carpinteria. pp 13-23
3. Bongiorno PF, Whyte RI, Lesser FJ, Moore JH, Orringer MB and Beer DG (1994) Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 107: 590-595
4. Buelzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Muller KM and Vogt-Moykopf I (1992) New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102-1110
5. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A and Minna J (1994) p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: a preliminary report of Lesg 871. Chest 106: 377-381
6. Chiba I, Takahashi T, Nau MM, D DA, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H. and et al (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer Lung Cancer Study Group. Oncogene 5: 1603-1610.
7. Chiu KY, Loke SI and Ho FC (1994) Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma comparison of cryostat and paraffin was sections and effect of fixation. J Clin Pathol 47: 117-121
8. Cox DR (1972) Regression models and life-tables (with discussion). J R Stat Soc B 34: 187-220
9. Gazdar AF (1992) The molecular biology of lung cancer Tohoku J Exp Med 168: 239-245
10. Hermanek P, Henson DE, Hutter RVP, and Sobin LH (1993) UICC TNM Supplement. Springer Verlag, Berlin, Heidelberg, New York 9-14
11. Holmes EC (1994) General principles of surgery quality control. Chest 106: 334-336
12. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R and et al. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1-4
13. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ and Marks JR (1990) Increased c-erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701-6707
14. Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H and Koeffler HP (1993) Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 53: 4053-4058
15. Johnson BE (1995) Biologic and molecular prognostic factors-impact on treatment of patients with non small cell lung cancer. Chest 107: 287-290
16. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 187-220
17. Keohavong P, DeMichele MA, Mclacrinos AC, Landreneau RJ, Weyant RJ and Siegfried JM (1996) Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2: 411-418
18. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L and Robinson RA (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5187
19. Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D and Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516-520
20. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K and Sekiya T (1992) Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52: 4799-804
21. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Chemnother Rep 50: 163-170
22. Minna JD (1993) The molecular biology of lung cancer pathogenesis. Chest 103: 449-456
23. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD and Gazdar AF (1991) ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51: 4999-5002
24. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85: 2018-2023
25. Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225-233
26. Mountain CF (1990) Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIa disease. Chest 97: 1045-1051
27. Naruke T, Goya T, Tsuchiya R and Suemasu K (1988) Prognosis and survival in resected lung carcinoma based on the new international staging system [published erratum appears in J Thorac Cardiovasc Surg 1989 Mar; 97(3):350]. J Thorac Cardiovasc Surg 96: 440-447
28. Parker SL, Tong T, Bolden S and Wingo PA (1996) Cancer statistics, 1996. CA Cancer J Clin 46: 5-27
29. Pfeiffer P, Clausen PP Andersen K and Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HFR-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74: 86-91
30. Press MF, Hung G, Godolphin W and Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777
31. Quinlan DC, Davidson AG, Summers CL, Warden HE and Doshi HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4231
32. Rodenhuis S and Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665-2669
33. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A and et al. (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330: 153-8
34. Rosell R, Monzo M, Pifarre A, Ariza A, Sanchez JJ, Moreno I, Maurel J, Lopez MP, Abad A and De Anta JM (1996) Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 2: 1083-1096
35. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Borresen AL. and Haugen A (1994) p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 54: 1551-1555
36. Sauter ER, Gwin JL, Mandel J and Keller SM (1995) p53 and disease progression in patients with non-small cell lung cancer. Surg Oncol 4: 157-161
37. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K and Roth JA (1989) Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49: 4968-4971
38. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler HJ, Cleary KR, Troster M, Siewert JR and Roth JA (1996) Mutations of p53 in Barrett's esophagus and Barren's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 111: 323-331; discussion 331-333
39. Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D and Hung MC (1992) Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcing 5: 213-218
40. Simon R and Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-85
41. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ and et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565
42. Spurrier JD and Hewett JE (1980) Two-stage test of independence using Kendall's statistic. Biometrics 36: 517-522
43. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K and Sasazuki T (1992) ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903-2906
44. Tateishi M, Ishida T, Mitsudomi T, Kaneko S and Sugimachi K (1991) Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372-1375
45. Top B, Mooi WJ, Klaver SG, Boerrigter L, Wisman P, Elbers HR, Visser S and Rodenhuis S (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 64: 83-91
46. Volm M, Ffferth T and Mattern J (1992) Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12: 11-20
47. World Health Organization (1982) The World Health Organization histologic typing of lung tumors. Am J Clin Pathol 77: 123-136